Intravenous immunoglobulins (IVIG) as long-term therapy in general myasthenia gravis: A case series

2008 ◽  
Vol 39 (01) ◽  
Author(s):  
A Wellek ◽  
C Eienbröker ◽  
B von Hagen ◽  
WH Oertel ◽  
N Sommer ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Case Series ◽  
Intravenous Immunoglobulins ◽  
Term Therapy ◽  
Long Term Therapy

119. Intravenous immunoglobulins (IVIG) as long-term therapy in general myasthenia gravis – A case series

2009 ◽  
Vol 120 (1) ◽  
pp. e50-e51
Author(s):  
A. Wellek ◽  
C. Eienbröker ◽  
B. von Hagen ◽  
W.H. Oertel ◽  
N. Sommer ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Case Series ◽  
Intravenous Immunoglobulins ◽  
Term Therapy ◽  
Long Term Therapy

Plasmaexchange in the Treatment of Myasthenia Gravis Associated with Thymoma

2003 ◽  
Vol 26 (2) ◽  
pp. 170-173 ◽  
Author(s):  
L. Gogovska ◽  
R. Ljapcev ◽  
M. Polenakovic ◽  
L. Stojkovski ◽  
M. Popovska ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Cholinesterase Inhibitors ◽  
Immunosuppressive Agents ◽  
Ventilatory Support ◽  
Term Therapy ◽  
First Year ◽  
Myasthenic Crisis ◽  
History Of ◽  
Long Term Therapy

Background All patients with thymomatous Myasthenia Gravis (MG) should undergo early and total thymectomy, but controversy abounds in the choice of chronic immunosuppressive agents. The value of plasmaexchange (PE) in MG has been clearly estabilshed in preoperative preparation and treatment of myasthenic crisis. Whether PE may be used in the chronic long-term therapy of patients with thymomatous MG in addition to conventional immunosuppressive agents and cholinesterase inhibitors is yet to be answered. Case history We present a 40-year old woman with an 11 year history of MG. Thymectomy was done during the first year of the disease and the histopathologic finding was thymoma. To sustain clinical remission after thymectomy she continued with immunosuppression with methylprednisolone and cyclosporin A (or azathioprine) in addition to cholinesterase inhibitors. Despite the almost continuous immunosuppression, the disease course continued with fluctuating myasthenic weakness which few times progressed to myasthenic crisis requiring mechanical ventilation. During myasthenic crisis we performed 6–8 plasmapheresis at 2–3 day intervals in addition to conventional immunosuppressive therapy. The disease rapidly worsened in January 2000 and we started with intermittent plasmapheresis (3–6 procedures at 2–3 day intervals, every 6–8 weeks) in order to sustain remission. With this therapeutic protocol, during 20 months follow-up we managed to prevent myasthenic crisis and to avoid ventilatory support. Conclusions Plasmaexchange could be used as a successful and safe therapeutic tool in chronic long-term therapy in addition to conventional immunosuppressive agents to sustain remission in patients with MG. This is particularly important in the treatment of patients with thymomatous MG because they have an increased frequency of myasthenic crisis and often respond poorly an to immunosuppression with steroids or other immunosuppressants.

scholarly journals Imaging in phenytoin induced neurotoxicity: a case series

2017 ◽  
Vol 6 (1) ◽  
pp. 355
Author(s):  
Manali Arora ◽  
Deb Kumar Boruah ◽  
Vishal Thakker ◽  
Sangeeta Bhanwra
Keyword(s):  
Side Effects ◽  
Megaloblastic Anemia ◽  
Cerebellar Atrophy ◽  
Case Series ◽  
Cerebral Atrophy ◽  
Term Therapy ◽  
Seizure Disorders ◽  
Anti Epileptic Drug ◽  
Long Term Therapy

Phenytoin is a commonly used anti-epileptic drug for various types of seizure disorders except for absent seizures. Long term dose dependant neurological side effects of phenytoin therapy include cerebellar atrophy, cerebral atrophy and brain stem atrophy. Skull hyperostosis, gum hypertrophy and megaloblastic anemia are other known effects of Long term therapy. We present four cases depicting clinical and neuroimaging findings of Phenytoin induced Toxicity.

Immunoregulation of Autoimmune Disorders: The Role of Intravenous Immunoglobulins

1993 ◽  
Vol 16 (5_suppl) ◽  
pp. 189-195 ◽  
Author(s):  
G. Luzi ◽  
R. Ferrara
Keyword(s):  
Hematologic Malignancies ◽  
Intravenous Immunoglobulins ◽  
Term Therapy ◽  
Immune Modulators ◽  
Bacterial Diseases ◽  
Immunoglobulin Preparations ◽  
Original Observation ◽  
Long Term Therapy

Modified and intact immunoglobulin preparations are available for therapeutic use. The administration of intravenous immunoglobulins (IVI G) gave positive results in Primary Immunodeficiency Syndromes (PIS) (prophylaxis of viral and bacterial diseases), in treatment of secondary immunodeficiencies (hematologic malignancies, bone marrow transplantation), and in some infections. Adverse reactions have been reported during IVIG infusions, but they are rarely serious and do not represent limiting conditions for a short or long term therapy. After the original observation in thrombocytopenic purpura, IVIG have been used as immune modulators in various autoimmune related disorders. Various mechanisms of action are proposed: blockade and down regulation of phagocytic function via Fc receptor, regulation of idiotype-anti idiotype network, suppression of idiotype synthesis, T-B cell interference towards antigen presentation, increase in suppressor lymphocytes, IVIG-cytokine interaction.

Antithrombotic Therapy for DVT/PE

1997 ◽  
Vol 17 (03) ◽  
pp. 161-162
Author(s):  
Thomas Hyers
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Oral Anticoagulants ◽  
Cost Effective ◽  
Therapeutic Agents ◽  
Great Promise ◽  
Term Therapy ◽  
Low Molecular Weight ◽  
Long Term Therapy

SummaryProblems with unfractionated heparin as an antithrombotic have led to the development of new therapeutic agents. Of these, low molecular weight heparin shows great promise and has led to out-patient therapy of DVT/PE in selected patients. Oral anticoagulants remain the choice for long-term therapy. More cost-effective ways to give oral anticoagulants are needed.

Office-based post-marketing surveillance study on the influence of long term therapy with aripiprazole in patients with schizophrenia

2007 ◽  
Vol 40 (05) ◽  
Author(s):  
M Kungel ◽  
A Engelhardt ◽  
T Spevakné-Göröcs ◽  
M Ebrecht ◽  
C Werner ◽  
...  
Keyword(s):  
Surveillance Study ◽  
Term Therapy ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Long Term Therapy
Sign in / Sign up

Export Citation Format

Share Document